Interferon Beta-1a

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Avonex, Rebif; Belgium: Avonex, Rebif; Bulgaria: Avonex, Rebif; Cyprus: Avonex; Czech Republic: Avonex, Rebif; Denmark: Avonex, Rebif; Estonia: Avonex, Rebif; Finland: Avonex, Rebif; France: Avonex, Rebif; Germany: Avonex, Rebif; Greece: Avonex, Rebif; Hungary: Avonex, Rebif; Ireland: Avonex, Rebif; Italy: Avonex, Rebif; Latvia: Avonex, Rebif; Lithuania: Avonex, Rebif; Luxembourg: Avonex, Rebif; Malta: Avonex, Rebif; Netherlands: Avonex, Rebif; Poland: Avonex, Rebif; Portugal: Avonex, Rebif; Romania: Avonex; Slovakia: Avonex, Rebif; Slovenia: Avonex, Rebif; Spain: Avonex, Rebif; Sweden: Avonex, Rebif; UK: Avonex, Rebif.

North America

Canada: Avonex, Rebif; USA: Avonex, Rebif.

Latin America

Argentina: Rebif; Brazil: Rebif; Mexico: Avonex, Xerfelan.


Japan: Avonex.

Drug combinations


Interferon Beta-1a: C~908~H~1406~N~246~O~252~S~7~ (protein moiety). Mw: 20024.85 (protein moiety). Interferon beta-1a is a glycosylate polypeptide consisting of 166 aa residues produced from cultured Chinese hamster ovary cells containing the engineered gene for human interferon beta. Glycosylation occurs at the asparagine (Asn) residue at position 80. The glycoprotein is approximately 89% protein and 11% carbohydrate by weight. Interferon β~1~ (human fibroblast protein moiety). CAS-145258-61-3 (1993).

Pharmacologic Category

Biologic Response Modifiers. (ATC-Code: L03AB07).

Mechanism of action

Alters expression and response to surface antigens and can enhance immune cell activities.

Therapeutic use

Treatment of relapsing forms of multiple sclerosis.

Pregnancy and lactiation implications

There are no adequate, well-controlled studies in pregnant women. Dose-related abortifacient activity reported in Rhesus monkeys. Not recommended during lactation (potential for serious adverse reactions).

Unlabeled use


Hypersensitivity to natural or recombinant interferons, human albumin, or any other component of the formulation.

Warnings and precautions

Allergic reactions, including anaphylaxis, reported. Autoimmune disorders, including idiopathic thrombocytopenia, hyper-/hypothyroidism and rarely autoimmune hepatitis reported. Pancytopenia (rare) and thrombocytopenia reported (use with caution in bone marrow suppression). Possible flu-like symptoms. Rare cases of severe hepatic injury, including hepatic failure, reported. Avoid use in severe psychiatric disorders and use caution in history of depression. Use with caution in pre-existing cardiovascular disease, including angina, heart failure, and/or arrythmia. Use with caution in hepatic impairment or in cases of alcohol abuse. Use with caution in history of seizure disorder. Some formulations contain albumin (contraindicated in albumin-sensitive patients).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart